Znachenie ul'trachuvstvitel'nogo metoda kolichestvennogo opredeleniya prostaticheskogo spetsificheskogo antigena v diagnostike retsidiva raka predstatel'noy zhelezy


Cite item

Full Text

Abstract

References

  1. Велиев Е.И. Оптимизация хирургического лечения больных локализованным раком предстательной железы. Дис. … д-ра мед. наук. СПб., 2003.
  2. Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152 (5 Pt 2): 1850-7.
  3. Liu L, Coker AL, Du XL et al. Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer. J Surg Oncol 2008; 97: 583-91.
  4. Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA 1997; 278 (1): 44-6.
  5. Kupelian PA, Katcher J, Levin HS et al. Stage T1-2 prostate cancer a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043-52.
  6. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42.
  7. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152 (5): 1831-6.
  8. Frazier HA, Robertson JE, Humphrey PA et al. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993; 149 (3): 516-8.
  9. Hull GW, Rabbani F, Abbas F et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167 (2 Pt 1): 528-34.
  10. Grossfeld GD, Chang JJ, Broering JM et al. Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy? Data from the CAPSURE database. Urology 2000; 56 (3): 430-5.
  11. Han M, Partin AW, Zahurak M et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169 (2): 517-23.
  12. Amling CL, Blute ML, Bergstralh EJ et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164 (2): 101-5.
  13. Roehl KA, Han M, Ramos CG et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172 (3): 910-4.
  14. Porter CR, Gallina A, Kodama K et al. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur Urol 2007; 52 (2): 446-52.
  15. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 1999; 162 (2): 293-306.
  16. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
  17. Oefelein MG, Smith N, Carter M et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995; 154 (6): 2128-31.
  18. Vessella RL. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem1993; 39 (10): 2035-9.
  19. Stamey TA, Graves HC, Wehner N et al. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993; 149 (4): 787-92.
  20. Ferguson RA, Yu H, Kalyvas M et al. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42 (5): 675-84.
  21. Ellis WJ, Vessella RL, Noteboom JL et al. Early detection of recurrent prostate cancer with an ultrasensitive hemiluminescent prostate-specific antigen assay. Urology 1997; 50 (4): 573-9.
  22. Doherty AP, Bower M, Smitрhetal GL. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000; 83 (11): 1432-6.
  23. Sakai I, Harada K, Kurahashi T et al. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized Prostate Cancer Urol Int 2006; 76 (3): 227-31.
  24. Shen S, Lepor H, Yaffee R et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005; 173: 777-80.
  25. Vesely S, Jarolim L, Babjuk M et al. Ultrasensitive prostate-specific antigen nadir and time to nadir as independent predictors of biochemical recurrence in patients after radical prostatectomy for localized prostate cancer. Eur Urol 2010; 10 (2): 274.
  26. Malik RD, Goldberg JD, Hochman T et al. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. Eur Urol 2011; 60 (3): 19-28.
  27. Witherspoon L, Lapeyrolerie T. Sensitive prostates pecific antigen measurements identify men with long disease free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol 1997; 157 (4): 1322-8.
  28. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
  29. Eisenberg ML, Davies BJ, Cooperberg MR et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010; 57 (4): 622-30.
  30. Haese A, Huland E, Graefen M et al. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol 1999; 161: 1206-11.
  31. Taylor JA, Koff SG, Dauser DA et al. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. BJU Int 2006; 98: 540-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964 от 18.12.2015 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies